Logo image of ETNB

89BIO INC (ETNB) Stock Fundamental Analysis

NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD

10.56  +3.43 (+48.11%)

Fundamental Rating

2

Overall ETNB gets a fundamental rating of 2 out of 10. We evaluated ETNB against 572 industry peers in the Biotechnology industry. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ETNB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ETNB has reported negative net income.
ETNB had a negative operating cash flow in the past year.
In the past 5 years ETNB always reported negative net income.
In the past 5 years ETNB always reported negative operating cash flow.
ETNB Yearly Net Income VS EBIT VS OCF VS FCFETNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -63.05%, ETNB is not doing good in the industry: 61.77% of the companies in the same industry are doing better.
ETNB has a Return On Equity (-76.42%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -63.05%
ROE -76.42%
ROIC N/A
ROA(3y)-43.73%
ROA(5y)-42.94%
ROE(3y)-55.08%
ROE(5y)-50.7%
ROIC(3y)N/A
ROIC(5y)N/A
ETNB Yearly ROA, ROE, ROICETNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

ETNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETNB Yearly Profit, Operating, Gross MarginsETNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

ETNB has more shares outstanding than it did 1 year ago.
ETNB has more shares outstanding than it did 5 years ago.
ETNB has a better debt/assets ratio than last year.
ETNB Yearly Shares OutstandingETNB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ETNB Yearly Total Debt VS Total AssetsETNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.02 indicates that ETNB is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.02, ETNB is in the better half of the industry, outperforming 75.22% of the companies in the same industry.
ETNB has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, ETNB is not doing good in the industry: 66.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.02
ROIC/WACCN/A
WACCN/A
ETNB Yearly LT Debt VS Equity VS FCFETNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 11.66 indicates that ETNB has no problem at all paying its short term obligations.
ETNB has a Current ratio of 11.66. This is amongst the best in the industry. ETNB outperforms 84.42% of its industry peers.
ETNB has a Quick Ratio of 11.66. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.66, ETNB belongs to the top of the industry, outperforming 84.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 11.66
ETNB Yearly Current Assets VS Current LiabilitesETNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

ETNB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.23%.
EPS 1Y (TTM)-46.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-208.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ETNB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-63.97%
EPS Next 2Y-22.61%
EPS Next 3Y-8.47%
EPS Next 5Y8.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETNB Yearly Revenue VS EstimatesETNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ETNB Yearly EPS VS EstimatesETNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ETNB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETNB Price Earnings VS Forward Price EarningsETNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETNB Per share dataETNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

ETNB's earnings are expected to decrease with -8.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.61%
EPS Next 3Y-8.47%

More info and screens

0

5. Dividend

5.1 Amount

ETNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

89BIO INC

NASDAQ:ETNB (1/27/2025, 11:49:06 AM)

10.56

+3.43 (+48.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners98.41%
Inst Owner Change0.28%
Ins Owners0.76%
Ins Owner Change-21.12%
Market Cap1.24B
Analysts82.67
Price Target30.89 (192.52%)
Short Float %6.75%
Short Ratio7.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-47.52%
Min EPS beat(2)-112.45%
Max EPS beat(2)17.4%
EPS beat(4)2
Avg EPS beat(4)-27.21%
Min EPS beat(4)-112.45%
Max EPS beat(4)17.4%
EPS beat(8)4
Avg EPS beat(8)-10.76%
EPS beat(12)7
Avg EPS beat(12)-5.3%
EPS beat(16)8
Avg EPS beat(16)-5.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.53%
PT rev (3m)-1.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-27.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-44.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.28
P/tB 3.28
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-3.02
Fwd EYN/A
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS3.22
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.05%
ROE -76.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.73%
ROA(5y)-42.94%
ROE(3y)-55.08%
ROE(5y)-50.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.66
Quick Ratio 11.66
Altman-Z 3.02
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.43%
Cap/Depr(5y)202.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-208.89%
EPS Next Y-63.97%
EPS Next 2Y-22.61%
EPS Next 3Y-8.47%
EPS Next 5Y8.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-126.22%
EBIT Next 3Y-26.43%
EBIT Next 5YN/A
FCF growth 1Y-241.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-241.16%
OCF growth 3YN/A
OCF growth 5YN/A